The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
D. Gajria
No relevant relationships to disclose
T. A. King
No relevant relationships to disclose
H. Pannu
No relevant relationships to disclose
R. Sakr
No relevant relationships to disclose
A. D. Seidman
No relevant relationships to disclose
A. Syldor
No relevant relationships to disclose
S. Patil
No relevant relationships to disclose
M. Maybody
No relevant relationships to disclose
L. Norton
No relevant relationships to disclose
N. Rosen
No relevant relationships to disclose
C. Hudis
No relevant relationships to disclose
S. Chandarlapaty
Research Funding - Pfizer